RCKT
Price
$17.45
Change
+$0.20 (+1.16%)
Updated
Nov 8 closing price
117 days until earnings call
ZYME
Price
$16.63
Change
-$0.14 (-0.83%)
Updated
Nov 8 closing price
Ad is loading...

RCKT vs ZYME

Header iconRCKT vs ZYME Comparison
Open Charts RCKT vs ZYMEBanner chart's image
Rocket Pharmaceuticals
Price$17.45
Change+$0.20 (+1.16%)
Volume$902.59K
CapitalizationN/A
Zymeworks
Price$16.63
Change-$0.14 (-0.83%)
Volume$678.74K
CapitalizationN/A
View a ticker or compare two or three
RCKT vs ZYME Comparison Chart
Loading...
RCKT
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
ZYME
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
VS
RCKT vs. ZYME commentary
Nov 09, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is RCKT is a Hold and ZYME is a StrongBuy.

COMPARISON
Comparison
Nov 09, 2024
Stock price -- (RCKT: $17.45 vs. ZYME: $16.63)
Brand notoriety: RCKT and ZYME are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: RCKT: 102% vs. ZYME: 101%
Market capitalization -- RCKT: $1.59B vs. ZYME: $1.15B
RCKT [@Biotechnology] is valued at $1.59B. ZYME’s [@Biotechnology] market capitalization is $1.15B. The market cap for tickers in the [@Biotechnology] industry ranges from $467.34B to $0. The average market capitalization across the [@Biotechnology] industry is $2.79B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

RCKT’s FA Score shows that 0 FA rating(s) are green whileZYME’s FA Score has 0 green FA rating(s).

  • RCKT’s FA Score: 0 green, 5 red.
  • ZYME’s FA Score: 0 green, 5 red.
According to our system of comparison, ZYME is a better buy in the long-term than RCKT.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

RCKT’s TA Score shows that 4 TA indicator(s) are bullish while ZYME’s TA Score has 4 bullish TA indicator(s).

  • RCKT’s TA Score: 4 bullish, 3 bearish.
  • ZYME’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, RCKT is a better buy in the short-term than ZYME.

Price Growth

RCKT (@Biotechnology) experienced а +2.77% price change this week, while ZYME (@Biotechnology) price change was +25.23% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.79%. For the same industry, the average monthly price growth was +13.74%, and the average quarterly price growth was +11.70%.

Reported Earning Dates

RCKT is expected to report earnings on Mar 06, 2025.

ZYME is expected to report earnings on May 08, 2023.

Industries' Descriptions

@Biotechnology (+2.79% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
RCKT($1.59B) has a higher market cap than ZYME($1.15B). ZYME YTD gains are higher at: 60.058 vs. RCKT (-41.775). ZYME has higher annual earnings (EBITDA): -110.13M vs. RCKT (-243.06M). ZYME has more cash in the bank: 297M vs. RCKT (279M). ZYME has less debt than RCKT: ZYME (20.2M) vs RCKT (25.8M). ZYME has higher revenues than RCKT: ZYME (62.2M) vs RCKT (0).
RCKTZYMERCKT / ZYME
Capitalization1.59B1.15B139%
EBITDA-243.06M-110.13M221%
Gain YTD-41.77560.058-70%
P/E RatioN/AN/A-
Revenue062.2M-
Total Cash279M297M94%
Total Debt25.8M20.2M128%
FUNDAMENTALS RATINGS
RCKT vs ZYME: Fundamental Ratings
RCKT
ZYME
OUTLOOK RATING
1..100
6578
VALUATION
overvalued / fair valued / undervalued
1..100
50
Fair valued
48
Fair valued
PROFIT vs RISK RATING
1..100
89100
SMR RATING
1..100
9793
PRICE GROWTH RATING
1..100
7635
P/E GROWTH RATING
1..100
10080
SEASONALITY SCORE
1..100
23n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ZYME's Valuation (48) in the Pharmaceuticals Major industry is in the same range as RCKT (50) in the Biotechnology industry. This means that ZYME’s stock grew similarly to RCKT’s over the last 12 months.

RCKT's Profit vs Risk Rating (89) in the Biotechnology industry is in the same range as ZYME (100) in the Pharmaceuticals Major industry. This means that RCKT’s stock grew similarly to ZYME’s over the last 12 months.

ZYME's SMR Rating (93) in the Pharmaceuticals Major industry is in the same range as RCKT (97) in the Biotechnology industry. This means that ZYME’s stock grew similarly to RCKT’s over the last 12 months.

ZYME's Price Growth Rating (35) in the Pharmaceuticals Major industry is somewhat better than the same rating for RCKT (76) in the Biotechnology industry. This means that ZYME’s stock grew somewhat faster than RCKT’s over the last 12 months.

ZYME's P/E Growth Rating (80) in the Pharmaceuticals Major industry is in the same range as RCKT (100) in the Biotechnology industry. This means that ZYME’s stock grew similarly to RCKT’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
RCKTZYME
RSI
ODDS (%)
N/A
Bearish Trend 2 days ago
78%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
87%
Bearish Trend 2 days ago
84%
Momentum
ODDS (%)
Bullish Trend 2 days ago
88%
Bullish Trend 2 days ago
80%
MACD
ODDS (%)
Bullish Trend 2 days ago
78%
Bullish Trend 2 days ago
73%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
83%
Bullish Trend 2 days ago
81%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
80%
Bullish Trend 2 days ago
82%
Advances
ODDS (%)
Bullish Trend 4 days ago
84%
Bullish Trend 3 days ago
83%
Declines
ODDS (%)
Bearish Trend 10 days ago
82%
Bearish Trend 9 days ago
84%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
80%
Bearish Trend 2 days ago
80%
Aroon
ODDS (%)
N/A
Bullish Trend 2 days ago
84%
View a ticker or compare two or three
Ad is loading...
RCKT
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
ZYME
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
FRBCX30.670.23
+0.76%
JHancock Regional Bank C
BRUMX17.880.09
+0.51%
MFS Blended Research Value Equity R4
JHQRX33.67N/A
N/A
JPMorgan Hedged Equity R6
JOMMX14.85N/A
N/A
JOHCM Emerging Mkts Discovery Instl
AIEVX24.69-0.20
-0.80%
Invesco EQV International Equity R5

RCKT and

Correlation & Price change

A.I.dvisor indicates that over the last year, RCKT has been loosely correlated with DNLI. These tickers have moved in lockstep 55% of the time. This A.I.-generated data suggests there is some statistical probability that if RCKT jumps, then DNLI could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RCKT
1D Price
Change %
RCKT100%
+1.16%
DNLI - RCKT
55%
Loosely correlated
+5.91%
NTLA - RCKT
54%
Loosely correlated
+4.56%
AXON - RCKT
52%
Loosely correlated
+28.89%
ALEC - RCKT
52%
Loosely correlated
+1.95%
RYTM - RCKT
52%
Loosely correlated
+5.37%
More